126 related articles for article (PubMed ID: 18990255)
1. Metabolism of no-carrier-added 2-[18F]fluoro-L-tyrosine in rats.
Aerts JJ; Plenevaux AR; Lemaire CF; Giacomelli F; Warnock GI; Phillips CL; Luxen AJ
BMC Med Phys; 2008 Nov; 8():4. PubMed ID: 18990255
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging.
Wester HJ; Herz M; Weber W; Heiss P; Senekowitsch-Schmidtke R; Schwaiger M; Stöcklin G
J Nucl Med; 1999 Jan; 40(1):205-12. PubMed ID: 9935078
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of 2-[18F]fluoro-L-tyrosine via regiospecific fluoro-de-stannylation.
Hess E; Sichler S; Kluge A; Coenen HH
Appl Radiat Isot; 2002 Aug; 57(2):185-91. PubMed ID: 12150277
[TBL] [Abstract][Full Text] [Related]
4. Effect of catechol-O-methyl transferase inhibition on peripheral and central metabolism of 6-[18F]fluoro-L-dopa.
Pauwels T; Dethy S; Goldman S; Monclus M; Luxen A
Eur J Pharmacol; 1994 May; 257(1-2):53-8. PubMed ID: 8082707
[TBL] [Abstract][Full Text] [Related]
5. [18F]Fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors.
Gründer G; Siessmeier T; Lange-Asschenfeldt C; Vernaleken I; Buchholz HG; Stoeter P; Drzezga A; Lüddens H; Rösch F; Bartenstein P
Eur J Nucl Med; 2001 Oct; 28(10):1463-70. PubMed ID: 11685488
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of an 18F-labeled dopa prodrug as a PET tracer for studying brain dopamine metabolism.
Ishiwata K; Shinoda M; Ishii S; Nozaki T; Senda M
Nucl Med Biol; 1996 Apr; 23(3):295-301. PubMed ID: 8782240
[TBL] [Abstract][Full Text] [Related]
8. Radiosynthesis and Preclinical Evaluation of an α
Krzyczmonik A; Keller T; López-Picón FR; Forsback S; Kirjavainen AK; Takkinen JS; Wasilewska A; Scheinin M; Haaparanta-Solin M; Sączewski F; Solin O
Mol Imaging Biol; 2019 Oct; 21(5):879-887. PubMed ID: 30710261
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vivo metabolism of 6-[18F]fluoro-L-dopa and [3H]L-dopa in rats.
Melega WP; Luxen A; Perlmutter MM; Nissenson CH; Phelps ME; Barrio JR
Biochem Pharmacol; 1990 Jun; 39(12):1853-60. PubMed ID: 2112915
[TBL] [Abstract][Full Text] [Related]
10. In vivo biodistribution of no-carrier-added 6-18F-fluoro-3,4-dihydroxy-L-phenylalanine (18F-DOPA), produced by a new nucleophilic substitution approach, compared with carrier-added 18F-DOPA, prepared by conventional electrophilic substitution.
Kuik WJ; Kema IP; Brouwers AH; Zijlma R; Neumann KD; Dierckx RA; DiMagno SG; Elsinga PH
J Nucl Med; 2015 Jan; 56(1):106-12. PubMed ID: 25500826
[TBL] [Abstract][Full Text] [Related]
11. A probe for intracerebral aromatic amino-acid decarboxylase activity: distribution and kinetics of [18F]6-fluoro-L-m-tyrosine in the human brain.
Nahmias C; Wahl L; Chirakal R; Firnau G; Garnett ES
Mov Disord; 1995 May; 10(3):298-304. PubMed ID: 7651447
[TBL] [Abstract][Full Text] [Related]
12. Radiolabeling and in vitro and in vivo evaluation of [18F]-FE-DABP688 as a PET radioligand for the metabotropic glutamate receptor subtype 5.
Honer M; Stoffel A; Kessler LJ; Schubiger PA; Ametamey SM
Nucl Med Biol; 2007 Nov; 34(8):973-80. PubMed ID: 17998101
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine.
Doudet DJ; Chan GL; Jivan S; DeJesus OT; McGeer EG; English C; Ruth TJ; Holden JE
J Cereb Blood Flow Metab; 1999 Mar; 19(3):278-87. PubMed ID: 10078880
[TBL] [Abstract][Full Text] [Related]
14. 18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters.
Goodman MM; Kilts CD; Keil R; Shi B; Martarello L; Xing D; Votaw J; Ely TD; Lambert P; Owens MJ; Camp VM; Malveaux E; Hoffman JM
Nucl Med Biol; 2000 Jan; 27(1):1-12. PubMed ID: 10755640
[TBL] [Abstract][Full Text] [Related]
15. Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo.
Heiss P; Mayer S; Herz M; Wester HJ; Schwaiger M; Senekowitsch-Schmidtke R
J Nucl Med; 1999 Aug; 40(8):1367-73. PubMed ID: 10450690
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and organ distribution of [18F]fluoro-Org 6141 in the rat: a potential glucocorticoid receptor ligand for positron emission tomography.
Visser GM; Krugers HJ; Luurtsema G; van Waarde A; Elsinga PH; deKloet ER; Groen MB; Bohus B; Go KG; Paans AM
Nucl Med Biol; 1995 Oct; 22(7):915-20. PubMed ID: 8547889
[TBL] [Abstract][Full Text] [Related]
17. Cerebral metabolism of L-[2-18F]fluorotyrosine, a new PET tracer of protein synthesis.
Coenen HH; Kling P; Stöcklin G
J Nucl Med; 1989 Aug; 30(8):1367-72. PubMed ID: 2787848
[TBL] [Abstract][Full Text] [Related]
18. 6-[18F]fluoro-L-m-tyrosine: metabolism, positron emission tomography kinetics, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lesions in primates.
Jordan S; Eberling JL; Bankiewicz KS; Rosenberg D; Coxson PG; VanBrocklin HF; O'Neil JP; Emborg ME; Jagust WJ
Brain Res; 1997 Mar; 750(1-2):264-76. PubMed ID: 9098552
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of in vitro decarboxylation and the in vivo metabolism of 2-18F- and 6-18F-fluorodopa in the hooded rat.
Cumming P; Häusser M; Martin WR; Grierson J; Adam MJ; Ruth TJ; McGeer EG
Biochem Pharmacol; 1988 Jan; 37(2):247-50. PubMed ID: 3124856
[TBL] [Abstract][Full Text] [Related]
20. No-carrier-added (NCA) (+/-)-N-(3-[18F]fluoropropyl)-N-normetazocine-synthesis and PET studies in a baboon.
Shiue CY; Teng RR; Bai LQ; Wolf AP; Arnett CD; Simon EJ
Int J Rad Appl Instrum B; 1987; 14(2):119-22. PubMed ID: 3496324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
